Deferiprone and Friedreich's Ataxia
Author Information
Author(s): Goncalves Sergio, Paupe Vincent, Dassa Emmanuel P, Rustin Pierre
Primary Institution: Inserm, U676, Hôpital Robert Debré, Paris, France
Hypothesis
Can deferiprone effectively target aconitase to treat Friedreich's ataxia?
Conclusion
Chelating excessive mitochondrial iron may help at some stages of Friedreich's ataxia, but it is crucial not to fully deplete mitochondrial iron to avoid negative effects.
Supporting Evidence
- Deferiprone treatment resulted in a significant loss of aconitase activity in both control and Friedreich's ataxia patient fibroblasts.
- The loss of aconitase activity was dose- and time-dependent.
- Aconitase activity is crucial for cell metabolism and its impairment was linked to decreased cell proliferation.
Takeaway
This study looked at how a drug called deferiprone affects a protein important for energy in cells from people with a disease called Friedreich's ataxia. It found that while the drug can help, too much of it can be harmful.
Methodology
The study involved cultured skin fibroblasts and neuroblastoma-derived cells treated with deferiprone to assess aconitase activity.
Limitations
The study was conducted in vitro, and the effects in human patients may vary.
Participant Demographics
Fibroblasts derived from healthy controls and two Friedreich's ataxia patients.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website